Trial Profile
A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), Post-Essential Thrombocythemia MF (PET-MF), MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Umbralisib (Primary)
- Indications Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions
- 10 Apr 2023 Results (n=37) assessing safety and efficacy of a umbralisib in combination with ruxolitinib in MF patients who had a suboptimal response or lost response to ruxolitinib, published in the Clinical Cancer Research
- 20 Jun 2022 Planned End Date changed from 1 Apr 2022 to 1 Dec 2024.
- 20 Jun 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.